awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q50041855-4AE7B643-0B55-4515-A661-121A00D1AB62
Q50041855-4AE7B643-0B55-4515-A661-121A00D1AB62
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50041855-4AE7B643-0B55-4515-A661-121A00D1AB62
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
P2860
Q50041855-4AE7B643-0B55-4515-A661-121A00D1AB62
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50041855-4AE7B643-0B55-4515-A661-121A00D1AB62
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
aadea0e14c012f120834770b0b7fe1815afb7a43
P2860
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors